Clinical trials: Filovirus Infections
Ebola Virus Disease
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Background: Ebola is a lethal disease. A lot is still unknown about Ebola and its long-term effects. Researchers want to learn what ill health conditions Ebola survivors have.
- Trial name
- NCT02431923
- Where
- 4 sites in United States, Liberia
- Volunteers
- 4,043 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)
Ebola virus is one of the most dangerous human pathogens and is an emerging public health problem in sub-Saharan Africa. Ebola virus disease (EVD) first appeared in 1976.
- Trial name
- NCT04409405
- Where
- 4 sites in Democratic Republic of the Congo
- Volunteers
- 787 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Ebola Virus Disease
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.
- Trial name
- NCT03462004
- Testing
- HPIV3/ΔHNF/EbovZ GP vaccine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with…
- Trial name
- EBOLAPED (NCT05130398)
- Testing
- rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens
- Where
- Gabon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Ebola Virus Disease
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z.
- Trial name
- NCT02485912
- Testing
- ChAd3-EBO Z, MVA-EBO Z
- Where
- Senegal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants
The purpose of this study is to assess the safety and reactogenicity of a heterologous 2-dose regimen utilizing Ad26.ZEBOV (first vaccination; Dose 1) and MVA-BN-Filo (second vaccination; Dose 2) administered intramuscularly (IM)…
- Trial name
- NCT03929757
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- 2 sites in Guinea, Sierra Leone
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Ebola Virus Disease
A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.
This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between…
- Trial name
- NCT02401373
- Testing
- Ad5-EBOV
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Ebola Virus Disease
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.
- Trial name
- BCV EBOV (NCT04268966)
- Testing
- Brincidofovir
- Sponsor
- Jazz Pharmaceuticals
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Ebola Virus Disease, Prevention
International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi
The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose
- Trial name
- NCT03072030
- Testing
- GamEvac-Combi (vaccine)
- Where
- 2 sites in Guinea, Russia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Marburg Virus Disease
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
- Trial name
- NCT06620003
- Testing
- cAd3-Marburg Vaccine
- Where
- 7 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Ebola Virus Disease
REVIVE (Response to the Ebola Virus Vaccine)
This study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine.
- Trial name
- NCT05992480
- Testing
- rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)
- Where
- Sierra Leone
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tulane University
Marburg Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7288 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01566877
- Testing
- AVI-7288
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Ebola
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
This is a randomized, observer-blind, placebo-controlled trial in male and female subjects ≥18 to <50 years of age. Subjects will be healthy adults based on history, physical examination, and baseline clinical laboratory testing.
- Trial name
- NCT02370589
- Testing
- Base Dose EBOV GP Vaccine, 2x Base Dose EBOV GP Vaccine, 4x Base Dose EBOV GP Vaccine
- Where
- 3 sites in Australia
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Novavax
Ebola Virus Disease
Efficacy of Favipiravir Against Severe Ebola Virus Disease
The purpose of this study is to explore the therapeutic efficacy of Favipiravir, a broad-spectrum antiviral drug against severe cases of Ebola Virus Disease (EVD), which is the most difficult aspect for clinical management of EVD…
- Trial name
- NCT02662855
- Testing
- WHO-recommended therapies, Favipiravir
- Volunteers
- 77 people
- Sponsor
- Beijing Institute of Pharmacology and Toxicology
Ebola Virus Disease
A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02533791
- Testing
- 4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV), 1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Virus Disease
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02326194
- Testing
- Low dose Ebola Zaire vaccine (Ad5-EBOV), High dose Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Ebola Disease, Marburg Disease
A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
This is a Phase 1, double-blind, randomized trial to evaluate the safety and immunogenicity of two heterologous and two homologous prime-boost regimens using MVA-BN(R)-Filo and Ad26.ZEBOV administered in different sequences at…
- Trial name
- NCT02891980
- Testing
- Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
Previous Ebola outbreaks have been limited to individual countries and contained by infection control activities. The current outbreak in West Africa is international, and air travel has resulted in a number of infected…
- Trial name
- NCT02296983
- Testing
- VSV-ZEBOV
- Where
- Kenya
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford